Loading
The poisons carried by antibody-drug conjugates are so toxic that only a few factories can make them, and they are booked years ahead. Making them in small continuous reactors would ease the bottleneck.
Capacity to make the toxins carried by ADCs, such as exatecan derivatives, maytansinoids and auristatins, is concentrated in a small number of contract manufacturers with multi-year lead times, and handling these toxins in batches, even in milligram quantities, requires costly containment. Continuous-flow chemistry in enclosed micro- or meso-reactors reduces the inventory of toxic intermediates at any moment, shrinks containment footprint and allows numbering-up rather than scale-up. The proposal is a pre-competitive programme to develop and regulator-qualify flow routes for the three most used payload classes and license them openly to manufacturers.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Payload (ADC), Enfortumab vedotin, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines.